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Abstract
Purpose Peptide receptor radionuclide therapy (PRRT)
using radiolabelled somatostatin analogues is a treatment
option for patients with disseminated neuroendocrine
tumours (NET). A combination treatment using the high-
energy
90Y beta emitter for larger lesions and the lower
energy
177Lu for smaller lesions has been postulated in
the literature.The aim of the study was to evaluate
combined
90Y/
177Lu-DOTATATE therapy in comparison
to
90Y-DOTATATE alone.
Methods Fifty patients with disseminated NETwere included
in the study prospectively and divided into two groups: group
A( n=25) was treated with
90Y-DOTATATE, whereas group
B( n=25) received the 1:1
90Y/
177Lu-DOTATATE. The
administered activity was based on 3.7 GBq/m
2 body surface
area in three to five cycles, with amino acid infusion for
nephroprotection.
Results The median overall survival time in group A was
26.2 months while in group B median survival was not
reached. Overall survival was significantly higher in group
B( p=0.027). Median event-free survival time in group A
was 21.4 months and in group B 29.4 months (p>0.1). At
the 12-month follow-up, comparison of group Avs group B
showed stable disease (SD) in 13 vs 16 patients, disease
regression (RD) in 5 vs 3 patients and disease progression
(PD) in 3 vs 4 patients; 4 and 2 patients died, respectively.
The 24-month follow-up results were SD in nine vs ten
patients, RD in one patient vs none and PD in four patients
in both groups; three and four patients died, respectively.
Side effects were rare and mild.
Conclusion The results indicate that therapy with tandem
radioisotopes (
90Y/
177Lu-DOTATATE) provides longer over-
all survival than with a single radioisotope (
90Y-DOTATATE)
and the safety of both methods is comparable.
Keywords Somatostatin receptor.Peptide receptor
radionuclide therapy.Neuroendocrine tumours.
90Y-DOTATATE. 177Lu-DOTATATE
Introduction
The choice of an appropriate treatment option as far as
patients with inoperable or metastatic neuroendocrine
tumours (NET) are concerned is limited. The response rate
of chemotherapy is only at the level of 20–35% [1],
effective in a minority of patients with poorly differentiated
NETs and is completely ineffective in the majority of well-
differentiated NETs. “Cold” somatostatin analogues exert a
good clinical effect, decreasing flushing, diarrhoea and
other symptoms of carcinoid syndrome [2, 3].
Worth mentioning is the fact that a prospective random-
ized study of the effect of octreotide LAR in the control of
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(PROMIDstudy)showedthatoctreotideLARinhibitstumour
growth in patients with well-differentiated metastatic midgut
NETs [4].
Peptide receptor radionuclide therapy (PRRT) with
radiolabelled somatostatin analogues has become an
established method of treatment of disseminated NET.
[
111In-diethylenetriaminepentaacetic acid (DTPA)
0]octreotide
firstly was used in some clinical trials, with regression
observed in 8% of patients. Because of the physical
characteristics and short range of the Auger electrons of
111In, the best results were observed in patients with small
tumours and relatively high tumour uptake [5]. Recently,
new somatostatin analogues that can be labelled with
beta-emitting radionuclides have been developed. Currently
90Ya n d
177Lu are used.
90Y emits beta particles with a high
maximum energy (Emax 2.27 MeV) and long maximum
particle range in tissues (10 mm), whereas
177Lu has lower
energy (Emax 0.497 MeV) and a shorter particle range in
tissues (maximum 2–4 mm).
This isotope has a small γ-emission which makes it
suitable for post-therapeutic scintigraphic imaging
[133 keV (6.5%); 208 keV (11%)]. Studies that evaluated
theefficacyoftotaldosesof7.4–20.2GBq[
90Y-DOTA
0,Tyr
3]
octreotide treatment have demonstrated a good response in
10–34% of patients [6–9]. Another large trial (MAURITIUS)
which evaluated response post
90Y-DOTA-(D)Na
1-lanreotide
(
90Y-DOTALAN) in 154 patients has shown a partial
response (PR) and disease stabilization in 14 and 41% of
patients, respectively [10].
Recent advances in somatostatin analogues have paved
the way to the development of octreotate, which can be
labelled with both
177Lu and
90Y radionuclides and is
characterized by a higher affinity for somatostatin receptor
type 2 leading to high tumour uptake.
The first clinical results of [
177Lu-DOTA
0,Tyr
3,Thr
8]
octreotate (DOTATATE) therapy with a cumulative dose of
22.2–29.6 GBq were described in 34 patients with gastro-
enteropancreatic (GEP) NET. The patients were followed
up 3–6 months after receiving the final dose [11]. At
3 months after the final administration, complete response
(CR) was found in 1 patient (3%), PR in 12 patients (35%),
stable disease (SD) in 14 patients (41%) and progressive
disease (PD) in 7 patients (21%). The side effects of PRRT
were few and mostly transient, with mild bone marrow
suppression and nephrotoxicity, which were the most
common finding.
de Jong et al. were the first to have described the use of
combination treatment consisting of 50%
177Lu-DOTATATE
and 50%
90Y-DOTATOC in rats, demonstrating that survival
rates were three times longer [12, 13]. To our knowledge,
there are no studies in the literature that evaluated the use of
this combination treatment in human subjects.
The aim of this study was to evaluate combined
90Y/
177Lu-DOTATATE therapy in patients with tumours of
various sizes and non-homogeneous receptor distribution in
comparison to
90Y-DOTATATE alone, using overall survival
(OS) and progression-free survival (PFS) as primary clinical
end points.
Materials and methods
The study was approved by the Ethics Committee of the
Medical University of Warsaw. All patients gave written
informed consent.
Patients
Fifty patients with histological confirmation of metastatic
NETs (WHO II) were enrolled in the study. At the time of
treatment all patients showed PD confirmed by CT
examination, somatostatin receptor scintigraphy (SRS)
and/or increasing blood concentration of chromogranin A
(CgA).
Patients were divided into two groups. Group A
consisting of 25 patients (11 men and 14 women) with
a mean age (± SD) of 57.3±10.6 years was treated with
90Y-DOTATATE. Group B consisting of 25 patients
( 9m e na n d1 6w o m e n )w i t ham e a na g e( ±S D )o f5 6 ±
11.6 years was treated with a combination treatment
including
90Ya n d
177Lu in one i.v. application.
The major criterion for inclusion into this study was the
benefit from PRRT therapy. Because of the fact that it was
the first PRRT study in Poland, patients had extended
disease. The Karnofsky index was used for estimating the
patients’ general condition.
The following inclusion criteria for therapy were used:
& SRS-positive disease with uptake in the tumour and
metastases higher that the liver, evaluated within
3 months before inclusion (qualitative analysis)
& Histological confirmation of NET; inoperable or
metastatic disease
& Haemoglobin level (Hb) ≥ 10 g/dl; leucocytes (WBC) ≥
2×10
9/l; thrombocytes (PLT) ≥ 90×10
9/l
& Calculated creatinine clearance (CrCl) > 40 ml/min
& Karnofsky performance status ≥ 60
& Life expectancy > 3 months
& No pregnancy or lactation
Allpatientsunderwentbloodtests(fullbloodcount,kidney,
liver functions tests and CgA) and staging prior to therapy
with the use of CT and SRS using
99mTc-HYNIC-TATE
(
99mTc-HYNIC-Tyr
3-octreotate) [14].
For patients receiving cold long-acting somatostatin
analogues, the radionuclide therapy was performed 5 weeks
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Novartis) and 3 weeks after lanreotide (Somatuline, Ipsen).
Patients who received chemotherapy were not treated with
PRRT until after a period of 3 months.
Patients were given a follow-up examination in the clinic
post PRRT at 3, 6, 12, 24 and 36 months using blood tests,
CT and
99mTc-HYNIC-TATE following the same protocols
as the ones used prior to therapy.
Radiopharmaceuticals
99mTc-HYNIC-TATE: the detailed method of kit prepa-
ration and labelling with
99mTc was presented before [14,
15]. Briefly, the peptide conjugate HYNIC-Tyr
3-octreo-
tate (piChem, Graz, Austria) was prepared in the dried kit
form under aseptic conditions (Institute of Atomic
Energy POLATOM, Poland) after adding commercially
available stannous chloride, mannitol, tricine, and N,N′-
ethylenediaminediacetic acid. Quality control was performed
by instant thin-layer chromatography silica gel (ITLC-SG)
strips (Pall) developed in 0.9% saline for the determination of
non-peptide-bound radioactivity.
The labelling yield efficiency exceeded 90% in all cases.
Tests for sterility and bacterial endotoxins were routinely
performed.
90Y-DOTATATE and
90Y/
177Lu-DOTATATE dried kits
containing 100 μg (DOTA-Tyr
3-octreotate) (piChem, Graz,
Austria) and 50.0 mg of commercially available ascorbic
acid were prepared under aseptic conditions. For labelling
the content of each kit vial was dissolved in not more than
0.5 ml of
90Y no-carrier-added chloride of desired radioac-
tivity (max. 6.5 GBq per kit) or
177Lu carrier-added
(specific activity of around 555 GBq/mg Lu) chloride
solution, both isotopes provided by the Institute of Atomic
Energy POLATOM, Poland. In case of low volume 0.9%
NaCl was used to fill up to 0.5 ml. Incubation was carried
out at 95°C for 25 min. After cooling down to room
temperature, the volume was increased up to 1.5–2.0 ml
with 0.9% NaCl. The preparation was sterilized by filtration
with 0.22-μm filters (Millipore) to sterile glass vials
followed by filter wash with 50 mg/ml ascorbic acid to
the final radioactive concentration of 740 MBq/ml. The
radiochemical purity (RCP) was assessed by HPLC
(column: Synergy 4 Fusion RP 80A 150×4.6 mm, flow
rate 0.6 ml/min, UV detection at 220 nm and radiometric
detection, solvent A: 0.1% trifluoroacetic acid in water,
solvent B: acetonitrile, gradient: 0 min 18% B; 9 min 60%
B; 12 min 60% B; 15 min 18% B; 21 min 18% B) and
Sep-Pak C18 (Waters) mini-column separation according to
the supplier’s instructions. The limit for RCP was over
99.0% for each
90Y- and
177Lu-labelled DOTATATE. The
specific activities obtained were on average 74.7 GBq/μmol
DOTATATE (in the range from 55.86 to 98.89 GBq/μmol)
and 38.20 GBq/μmol (in the range from 23.55 to
44.83 GBq/μmol) for
90Y- and
177Lu-labelled DOTATATE,
respectively.
90Y-DOTATATE was administered as such
while the mixed doses of
90Y/
177Lu-DOTATATE were
prepared from each
90Y- and
177Lu-labelled DOTATATE
solution with equal radioactivity (1 GBq
177Lu/1 GBq
90Y).
Treatment
Therapy was performed on an outpatients basis. Mixed
amino acid (1,000 ml Vamin 18, Fresenius Kabi) and
Ringer’s solutions (500 ml) were infused over 8 h for
kidney protection, with infusion of 200 ml prior to
administrationofthetreatment[16–19]. Before administration
of the radiopharmaceutical, ondansetron (8 mg, Zofran,
Glaxo Wellcome, Atossa, Anpharm SA) was injected
intravenously to prevent nausea and vomiting.
Treatment sessions were repeated, up to a total
calculated dose of 7.4 GBq/m
2. The injected activity per
one course was 2.2–3.7 GBq. With respect to
90Y/
177Lu-
DOTATATE treatment, 50% activity of
90Y-DOTATATE
and 50% activity of
177Lu-DOTATATE were injected. The
median period between the treatment courses was 40 and
49 days, respectively.
Post-therapy imaging
A whole-body scan (256 × 256 matrix, 8-min acquisi-
tion per cm) and single photon emission computed
tomography (SPECT) acquisition of the abdomen (128 ×
128 matrix, 6º × 60 s) were performed using the dual-
head Varicam camera (GE) with parallel-hole, high-
energy, general purpose collimators [energy window
centred on
177Lu photopeak (216 keV) and a ±10%
window width].
Bremsstrahlung imaging whole-body scans in 256 × 256
matrix, 8 cm/min was performed in ten patients 24 h post
90Y-DOTATATE therapy again using the dual-head Varicam
camera (GE) with a parallel-hole, low-energy, high-
resolution collimator (energy window centred on 100 keV
with a window width of ±35%) [20].
Evaluation of results and assessment of clinical benefit
The staging of disease and treatment response were
evaluated at 3, 6, 12, 24 and 36 months follow-up.
Blood tests were repeated every 7 days, others between
14 and 21 days after each cycle of therapy, and finally 3,
6, 12, 24 and 36 months after the completion of the
therapy. Response to treatment on CT was defined
according to Response Evaluation Criteria in Solid
Tumors (RECIST). Side effects were scored according
to the WHO criteria.
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PRRT to the first evidence of progression or relapse, or to
death. OS was defined as the time from PRRT to death
from any cause.
The following progression criteria were defined:
& In patients with clinical symptoms of carcinoid
syndrome, aggravation of flushing, diarrhoea or lacrima-
tion occurrence
& Increased level of CgA of more than 50% above a
previously measured value on follow-up (3, 6 and
12 months following therapy)
& The increase of two-dimensional tumour diameters of
more than 30% on enhanced three-phase CT
& The detection of new tumour foci on SRS with
99mTc-
HYNIC-TATE on planar whole-body and SPECT imaging
of the abdomen (if needed, SPECT of the chest)
Statistical methods
Means and standard deviations, medians and quartiles or
frequencies depending on the parameters’ distribution were
used to summarize patient characteristics. The difference
between comparable parameters was checked on the basis
of Mann-Whitney and Wilcoxon tests.
OS, EFS and probability of 24-month survival were
calculated on Kaplan-Meier estimator and compared via the
log-rank test [21]. The multiple proportional hazards
regression model (Cox analysis) was used for the analysis
of OS and EFS. The association of chosen clinical
predictors with OS and EFS was verified using the multiple
proportional hazards regression model. No model reduction
was performed to allow the adjustment of the effect of
quality measurements for the effect of possible clinical
predictors.
90Y-DOTATATE (n=25)
90Y/
177Lu-DOTATATE (n=25)
Age range 37–75 31–73
Mean ± SD 57.3±10.6 55±11.5
Sex: female 14 (56%) 16 (64%)
Female age range 37–75 39–73
Mean ± SD 58.2±2.9 58.5±12.4
Male age range 37–70 39–64
Mean ± SD 54.3±10.8 53.7±9.3
Foregut 12 (48%) 13 (52%)
Midgut 11 (44%) 8 (32%)
Hindgut 1 (4%) 1 (4%)
MEN 1 0 1 (4%)
von Hippel-Lindau syndrome 0 1 (4%)
Without primary 1 (4%) 1 (4%)
Size of lesion (CT in mm), range 10–166 16–155
Median (25%, 75%) 50 (39, 91) 47 (30, 75)
Number of lesions
1 2 (8%) 0
1–10 9 (36%) 8 (32%)
>10 14 (56%) 17(68%)
Site of metastases
Liver 19 (76%) 20 (80%)
Bones 4 (16%) 7 (28%)
Lymph node 10 (40%) 7 (28%)
CgA (U/l )
Range 5.1–11,477 24–4,572
Median (25%, 75%) 423 (272.6, 1,000) 179 (71, 417.8)
Surgery 20 19
Chemotherapy 8 12
“Cold” somatostatin analogues 9 6
Table 1 Patient characteristics
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residuals and in cases of violation the stratified model was
fitted [22].
Calculations were done in Stata v.10.1 software
(Stata Statistical Software: Release 10,Stata Corporation
LP, College Station, TX, USA).
Results
Patient characteristics
In the group treated with
90Y-DOTATATE alone, 12
patients were diagnosed with foregut NETs (9 pancreas
NET: 3 gastrinoma, 1 insulinoma, 5 non-functioning
tumours; 3 bronchial NET), 11 patients with midgut NETs
(8 carcinoid, 3 small intestinal), 1 patient with hindgut NET
(rectal NET) and 1 patient with unknown primary tumours.
In the group treated with a combination of
90Y/
177Lu-
DOTATATE, 13 patients were diagnosed with foregut
NETs (9 pancreas NET: 1 glucagonoma, 4 gastrinoma, 4
non-functioning tumours; 3 bronchial NET, 1 epiglottal
NET), 8 patients with midgut NETs (7 carcinoids, 1 small
intestinal), 1 patient with hindgut NET (rectal NET), 2
patients with other tumours [1 patient with multiple
endocrine neoplasia (MEN 1), 1 patient with von
Hippel-Lindau syndrome] and 1 patient with unknown
primary tumours.
Fig. 1 A 58-year-old man with
multiple liver and peritoneum
metastases of gastrinoma. a SRS
with
99mTc-HYNIC-TATE
before treatment with uptake
in metastatic lesions in liver
and peritoneum. b 24-h
post-therapeutic image
after administration of
90Y-DOTATATE using
bremsstrahlung
Fig. 2 A 42-year-old man with
multiple bone metastases of
atypical bronchial carcinoid
tumour without hormonal
activity. a SRS with
99mTc-HYNIC-TATE before
treatment with uptake in
metastatic lesions in bone.
b 24-h post-therapeutic
image after administration
of
90Y/
177Lu-DOTATATE
using
177Lu photopeak
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parameters (age, sex, origin of tumours, size of metastases
on CT, CgA, number and localization of metastases and
treatment before PRRT). A Karnofsky performance status ≥
80 was seen in the majority of patients; only two patients in
both groups had a status ≥ 60.
Detailed patient characteristics are listed in Table 1.
Post-therapeutic imaging
Post-therapeutic scans were performed to evaluate the
biodistribution of tracer. In all cases increased uptake in the
tumours and metastases was observed, compared to the liver
background on qualitative analysis. The results of post-
therapeutic images in all cases were comparable with the
distribution of disease on
99mTc-HYNIC-TATE imaging
(Figs. 1 and 2). Following post-therapeutic scans uptake in
the majority of patients was unchanged. Only in two patients
(one in group A and one in group B) were decreasing uptake
and decrease in size of the liver metastatic lesions observed.
Results of therapy
The median follow-up observation period in group A was
37.7 months and the interquartile range (IQR) for the
observation period was 20.5–46.7 months. In group B the
median follow-up observation period was 34.6 months and
the IQR was 25.2–39.5 months.
In the
90Y-DOTATATE group of patients OS was
26.2 months. In patients treated with
90Y/
177Lu-DOTATATE,
median survival was not reached, because less than 50%
patients died. The survival plot depicting OS and the
Fig. 4 Kaplan-Meier estimators of EFS
Fig. 3 Kaplan-Meier estimators of OS
Fig. 5 Comparison of the PRRT results (SD, RD, PD and patients
who died): a 12 months, b 24 months, c 36 months follow-up
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treated with
90Y/
177Lu-DOTATATE was statistically signif-
icantly longer (p<0.027) (Fig. 3). The calculated proba-
bility of 24-month survival was 62% in the group treated
with
90Y-DOTATATE and 89% in those treated with
90Y/
177Lu-DOTATATE.
Median EFS in the
90Y-DOTATATE and
90Y/
177Lu-
DOTATATE groups was 21.4 and 29.4 months, respectively;
the difference in EFS was not statistically significant (Fig. 4).
The probability of 24-month PFS was 44 and 57%,
respectively.
At the 12-month follow-up in the
90Y-DOTATATE group
vs the
90Y/
177Lu-DOTATATE group, the following was
observed: SD in 13 vs 16 patients, disease regression (RD)
in 5 vs 3 patients, and PD in 3 vs 4 patients; 4 and 2
patients died, respectively (Fig. 5a).
Atthe24-monthfollow-up:SDwasobservedinninevsten
patients, RD in patients in the group treated with
90Y/
177Lu-
DOTATATE and progression in four patients in both groups;
five and four patients died, respectively (Fig. 5b).
At the 36-month follow-up, SD was noted in six vs eight
patients and PD in one patients in both groups; four and
four patients died, respectively (Fig. 5c).
CT showed regression in size of the biggest lesions in the
group treated with
90Y-DOTATATE from median 50 to
44 mm and in the group treated with
90Y/
177Lu-DOTATATE
from 47 to 33 mm (Fig. 6). The changes in both groups are
not statistically significant. Correlation between tumour size
before and after therapy is shown in Fig. 7.
The patients in our study were not randomized to either
group A or B but were treated first with
90Y-DOTATATE
(group A) and patients who presented later were treated
with
90Y/
177Lu-DOTATATE. For this reason we used the
Cox analysis to evaluate the effects of the relevant
prognostic factors on the survival times in each group of
patients and the independence of these variables.
In the proportional hazards regression model for OS the
radionuclides used, age of patients, sex, CgA level, number
of lesions and size of maximal lesion were included. The
model for OS was stratified by number of lesions due to a
violated proportional hazards assumption.
Treatment is statistically significantly associated with
OS, but not with EFS (Tables 2 and 3). Statistical analysis
led to lower probability of death in the group treated with
tandem
90Y/
177Lu-DOTATATE than with
90Y-DOTATATE
alone [hazard ratio (HR)=5.74, 95% confidence interval
(CI) 1.63–20.2, p=0.006] (Table 2). Effects of treatment on
SRS are shown in Fig. 8.
Side effects of treatment with
90Y-DOTATATE
and
90Y/
177Lu-DOTATATE
The treatment was well tolerated. No severe adverse events
occurred. Nausea and vomiting during administration of
Fig. 7 Correlation between tumour size and type of therapy before
and 3–6 months after therapy
Fig. 6 Changes on CT in the size of the biggest tumours 3–6 months
after completed therapy. The line represents median reduction of
tumour size in % for both groups
Table 2 Cox proportional hazards regression model of OS
OS HR (95% CI) p
177Lu/
90Yv s
90Y 5.74 (1.63–20.2) 0.006
Age ≥ 56 vs < 56 >0.1
Sex M vs F >0.1
Size of lesion ≥ median vs < median >0.1
Number of lesions > median vs < median >0.1
CgA > median vs < median >0.1
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patients (40%) with the same frequency in both groups. All
cases of nausea and vomiting were successfully treated with
ondansetron. Mild pain (no treatment required) at the site of
the tumour was observed in 4 of 25 patients (16%) treated
with
90Y-DOTATATE within the first 48 h post-treatment
and in 3 of 25 patients (12%) treated with
90Y/
177Lu-
DOTATATE within the first 72 h after treatment. In 2 of 50
patients (4%) chest pain immediately after administration
was observed (1 patient treated with
90Y-DOTATATE and 1
patient treated with
90Y/
177Lu-DOTATATE). Liver tests
were stable. According to WHO haematological toxicity
criteria, haematological toxicity grade 3 was seen only in
one patient treated with
90Y-DOTATATE (patient received
chemotherapy before PRRT). Toxicity grades 1 and 2 were
seen with nearly the same frequency in both groups (grade
1 in six patients in the group treated with
90Y-DOTATATE
vs seven patients in the group treated with
90Y/
177Lu-
DOTATATE and grade 2 in three patients vs four patients,
respectively) and without clinical symptoms. The decrease
of WBC, RBC and PLT after therapy was similar in both
groups. During treatment CrCl was stable in 15 patients
treated with
90Y-DOTATATE and in 13 patients treated with
90Y/
177Lu-DOTATATE. Deterioration in kidney function
was observed in three patients in each group, measured by
creatinine level and calculated CrCl (the maximum
observed changes in CrCl in the group treated with
90Y-DOTATATE was from 111 ml/min prior to therapy
which declined to 54 ml/min at the 36-month follow-up
and in the group treated with
90Y/
177Lu-DOTATATE
from 106 ml/min prior to therapy to 67 ml/min at the 36-
month follow-up). These patients received chemotherapy
(etoposide+cisplatin) prior to PRRT. In two patients
treated with
90Y/
177Lu-DOTATATE transient deterioration
in kidney function was observed.
Totally, for all patients at the 36-month follow-up the
mean creatinine level increase was 0.07 mg/dl per year and
CrCl decrease 5.1 ml/min per year.
Discussion
PRRT using radiolabelled somatostatin analogues is a
promising new treatment option for patients with metastatic
or inoperable somatostatin receptor-positive NETs. Clinical
trials and radiochemistry examinations have demonstrated
Table 3 Cox proportional hazards regression model of EFS
EFS HR (95% CI) p
177Lu/
90Yv s
90Y >0.1
Age ≥ 56 vs < 56 >0.1
Sex M vs F >0.1
Size of lesion ≥ median vs < median >0.1
Number of lesions > median vs < median 7.2 (1.76–29.4) 0.006
CgA > median vs < median >0.1
Fig. 8 A 62-year-old woman with multiple bone and liver metastases
of pancreas neuroendocrine carcinoma without hormonal activity. a
SRS with
99mTc-HYNIC-TATE before treatment with uptake in
metastatic lesions in bone and liver. b 12-month follow-up shows reduced
number of metastases, with only a few visible in bone. c 24-month
follow-up shows nearly complete response to treatment
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177Lu and
90Y are suitable beta-emitting radio-
nuclides for PRRT. It is speculated in the literature that
90Y
emits beta particles with longer path lengths and higher
energies which may be preferable for larger tumours, while
177Lu with shorter beta particle range and longer half-life
may be preferable for small tumours. In our study we did
not observe an influence of beta particle energy on size
response of tumours (Figs. 6 and 7). Based on the fact that
177Lu has a longer half-life, it will take longer to deliver the
same dose as
90Y. Therefore, in patients with tumours of
various sizes and non-homogeneous receptor distribution, a
possible solution might be the use of a combination of
radionuclides [19, 23, 24].
Another option is a sequential administration of these
analogues, e.g. initial administration of
90Y-labelled analogue
to treat the larger tumours, followed by
177Lu-labelled
analogue in the next treatment cycle(s) for treatment of
smaller metastases.
In our study we used OS and EFS as primary end points
to assess the effect of
90Y-DOTATATE only in comparison
to combined
90Y/
177Lu-DOTATATE therapy. As we know,
this the first study in the literature that evaluated the role of
combined PRRT in disseminated NETs. The OS after
treatment in our patients was longer in the patients treated
with
90Y/
177Lu-DOTATATE in comparison to treatment
with
90Y-DOTATATE only and longer than has previously
been reported in the literature [25].
We observed longer EFS in the group treated with
90Y/
177Lu-DOTATATE compared to treatment with
90Y-DOTATATE alone, but this was not statistically signifi-
cant. This difference might be significant if the period of
follow-upislonger.Inaddition,patientswerenotrandomized,
as group Awas treated first and then group B at a later date.
A study by Kwekkeboom et al. about treatment with
177Lu-DOTATATE [26] reported that median PFS was
33 months and median OS was 46 months. This may be
related to a longer period of follow-up.
No serious adverse events occurred after treatment with
either
90Y/
177Lu-DOTATATE or
90Y-DOTATATE. The
toxicity as assessed according to the WHO criteria was
limited and without clinical manifestations in both groups
of patients. Therefore, we conclude that treatment with
90Y/
177Lu-DOTATATE in disseminated or inoperable
patients with NETs is feasible and safe. Clinical improvement
could be observed and most patients have benefited from the
treatment. We have demonstrated that this therapy is superior
to
90Y-DOTATATE alone with a longer period of OS.
In additionthe labelling and administrationof DOTATATE
in combined therapy was straightforward, and its application
was safe.
The major limitation of this analysis, like other
published PRRT studies, is the lack of randomization.
CT treatment response is limited to anatomical changes
and it is not sensitive enough to depict functional changes.
That is why, for better inclusion and evaluation of therapy
response,positronemissiontomography(PET)/CTtechniques
with
68Ga-DOTATATE should be used, which was not
available in our department during the study.
Conclusion
The results indicate that therapy with tandem radioisotopes
(
90Y/
177Lu-DOTATATE) provides longer OS than with a
single radioisotope (
90Y-DOTATATE) and the safety of
both methods is comparable. It seems that OS time and EFS
time rather than WHO criteria for determining tumour
burden should be used to assess the response to therapy.
However, more extensive studies with a larger number of
patients are required both to establish the proportion of each
isotope to be used in this dual therapy and to evaluate EFS
over a longer period of follow-up.
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